SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?


To: jim black who wrote (563)1/22/1998 1:32:00 AM
From: Vector1  Read Replies (1) | Respond to of 1686
 
Jim,
Sorry I was not clear. By off label I meant use of Avonex at earlier stages of the disease. My understanding is that Avonex is approved only for relapsing and remitting form of the disease. The company is in clinicals and believes it will show efficacy to prescribing Avonex to patients earlier in the disease life cycle. Undoubtedly the HMOs and insurance companies will resist earlier use of the drug.
V1